

# Livio Trentin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5959483/livio-trentin-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186  
papers

5,430  
citations

35  
h-index

69  
g-index

199  
ext. papers

6,549  
ext. citations

5  
avg, IF

4.78  
L-index

#	Paper	IF	Citations
186	BRAF mutations in hairy-cell leukemia. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2305-15	59.2	791
185	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3746-52	2.2	667
184	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , <b>2014</b> , 99, 1107-13	6.6	179
183	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 369-378	15.9	178
182	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. <i>Blood</i> , <b>2012</b> , 119, 192-5	2.2	140
181	Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. <i>Blood</i> , <b>2004</b> , 104, 502-8	2.2	125
180	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , <b>2020</b> , 34, 2354-2363	10.7	118
179	Multiple myeloma cell survival relies on high activity of protein kinase CK2. <i>Blood</i> , <b>2006</b> , 108, 1698-707	2.2	113
178	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , <b>2016</b> , 127, 1007-16	2.2	110
177	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , <b>2019</b> , 133, 1205-1216	2.2	94
176	Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo. <i>Cancer Cell</i> , <b>2017</b> , 31, 516-531.e10	24.3	92
175	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. <i>Blood</i> , <b>2003</b> , 102, 1797-805	2.2	87
174	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 480-6	7.1	86
173	Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 172, 1290-8	10.2	70
172	Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1919-27	2.2	64
171	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. <i>Blood</i> , <b>2013</b> , 121, 3843-54, S1	2.2	61
170	Protein kinase CK2 inhibition down modulates the NF- $\kappa$ B and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e75280	3.7	59

169	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , <b>2015</b> , 125, 856-9	2.2	55
168	Spontaneous production of interleukin-6 by alveolar macrophages from human immunodeficiency virus type 1-infected patients. <i>Journal of Infectious Diseases</i> , <b>1992</b> , 166, 731-7	7	53
167	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 112, 4665-74	2.2	50
166	CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 964-71	12.9	49
165	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4015-4022	2.2	49
164	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , <b>2016</b> , 3, e467-e479	14.6	44
163	Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. <i>Blood</i> , <b>2017</b> , 130, 643-654	2.2	43
162	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. <i>Haematologica</i> , <b>2012</b> , 97, 56-63	6.6	43
161	Circular RNA differential expression in blood cell populations and exploration of circRNA deregulation in pediatric acute lymphoblastic leukemia. <i>Scientific Reports</i> , <b>2019</b> , 9, 14670	4.9	42
160	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. <i>British Journal of Haematology</i> , <b>1999</b> , 106, 662-8	4.5	41
159	CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. <i>American Journal of Medicine</i> , <b>1993</b> , 95, 466-72	2.4	41
158	Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. <i>European Journal of Haematology</i> , <b>2009</b> , 83, 406-19	3.8	40
157	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 2053-2060	6.6	39
156	S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. <i>Blood</i> , <b>2012</b> , 120, 4391-9	2.2	38
155	Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. <i>PLoS ONE</i> , <b>2010</b> , 5, e13552	3.7	38
154	The neutrophil-activating protein of <i>Helicobacter pylori</i> (HP-NAP) activates the MAPK pathway in human neutrophils. <i>European Journal of Immunology</i> , <b>2003</b> , 33, 840-9	6.1	38
153	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. <i>Haematologica</i> , <b>2015</b> , 100, e515-8	6.6	37
152	Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 68, 823-9	4	37

151	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. <i>Journal of Hematology and Oncology</i> , <b>2013</b> , 6, 78	22.4	35
150	Interleukin-15: a novel cytokine with regulatory properties on normal and neoplastic B lymphocytes. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 27, 35-42	1.9	35
149	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 594-602	4.5	35
148	Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. <i>Journal of Leukocyte Biology</i> , <b>2007</b> , 82, 946-55	6.5	35
147	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. <i>Blood</i> , <b>2005</b> , 105, 931-9	2.2	35
146	Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. <i>Blood</i> , <b>2015</b> , 125, 3747-55	2.2	33
145	Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , <b>2015</b> , 75, 4153-63	10.1	32
144	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , <b>2021</b> , 35, 737-746	10.7	32
143	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. <i>BMC Cancer</i> , <b>2010</b> , 10, 526	4.8	30
142	Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 697-705	6.6	30
141	Towards a new age in the treatment of multiple myeloma. <i>Annals of Hematology</i> , <b>2007</b> , 86, 159-72	3	28
140	Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca <sup>2+</sup> -dependent death of cancer cells. <i>EMBO Reports</i> , <b>2020</b> , 21, e49117	6.5	28
139	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , <b>2021</b> , 137, 1365-1376	2.2	26
138	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 229-233	4.5	25
137	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2014</b> , 99, 881-7	6.6	25
136	HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen. <i>PLoS ONE</i> , <b>2012</b> , 7, e39902	3.7	25
135	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , <b>2018</b> , 103, 1209-1217	6.6	24
134	Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2014</b> , 99, 1069-77	6.6	24

133	Inactivation of CK1 $\beta$ in multiple myeloma empowers drug cytotoxicity by affecting AKT and Eatenin survival signaling pathways. <i>Oncotarget</i> , <b>2017</b> , 8, 14604-14619	3.3	24
132	Gamma delta T cell receptor subsets in the lung of patients with HIV-1 infection. <i>Cellular Immunology</i> , <b>1994</b> , 153, 194-205	4.4	23
131	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. <i>European Journal of Cancer</i> , <b>2017</b> , 72, 103-111	7.5	22
130	Biophysical characterization and expression analysis of Kv1.3 potassium channel in primary human leukemic B cells. <i>Cellular Physiology and Biochemistry</i> , <b>2015</b> , 37, 965-78	3.9	22
129	Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 875-83	2.2	21
128	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. <i>Cancers</i> , <b>2019</b> , 11,	6.6	21
127	Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1249-1254	8.9	20
126	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5292-5301	12.9	20
125	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 612-20.e1-5	2	19
124	Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia. <i>Immunogenetics</i> , <b>2015</b> , 67, 61-6	3.2	19
123	Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. <i>Cancers</i> , <b>2019</b> , 11,	6.6	19
122	HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3089-3100	7.5	18
121	Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. <i>Haematologica</i> , <b>2010</b> , 95, 1722-9	6.6	18
120	Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). <i>Blood</i> , <b>2005</b> , 106, 3926-31	2.2	18
119	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 150-156	8.7	17
118	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , <b>2020</b> , 136, 763-766	2.2	17
117	Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-ALL). <i>Biochemical Pharmacology</i> , <b>2018</b> , 153, 230-241	6	17
116	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. <i>Cell Death Discovery</i> , <b>2019</b> , 5, 98	6.9	17

115	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. <i>Haematologica</i> , <b>2014</b> , 99, 1826-33	6.6	17
114	Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. <i>Haematologica</i> , <b>2017</b> , 102, 1401-1412	6.6	17
113	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 659-72	4.5	17
112	CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. <i>Respiratory Research</i> , <b>2005</b> , 6, 20	7.3	17
111	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 81-93	4.5	16
110	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 193-197	4.5	16
109	HIF-1 $\beta$ /Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cells. <i>Theranostics</i> , <b>2019</b> , 9, 4860-4877	12.1	16
108	SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection. <i>Experimental Biology and Medicine</i> , <b>2012</b> , 237, 793-802	3.7	16
107	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , <b>2017</b> , 35, 925-928	1.3	15
106	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 289-93	7.1	15
105	High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 723-9	13.4	15
104	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. <i>Oncotarget</i> , <b>2017</b> , 8, 110727-110731	3.3	15
103	Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. <i>Scientific Reports</i> , <b>2016</b> , 6, 34449	4.9	14
102	Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 955-60	7.1	14
101	T cells in the lung of patients with hypersensitivity pneumonitis accumulate in a clonal manner. <i>Journal of Leukocyte Biology</i> , <b>2004</b> , 75, 798-804	6.5	13
100	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. <i>Cancer</i> , <b>1989</b> , 64, 667-72	6.4	13
99	Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. <i>Cancer</i> , <b>1989</b> , 64, 2019-23	6.4	13
98	Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells. <i>Oncotarget</i> , <b>2016</b> , 7, 57086-57098	3.3	13



97	Role of and the axis in regulating telomerase expression in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2017</b> , 102, e253-e256	6.6	12
96	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 678-685.e4	2.5	12
95	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4 Infant ALL. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1705-1716	6.1	12
94	New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures. <i>BMC Genomics</i> , <b>2007</b> , 8, 188	4.5	12
93	Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events. <i>Leukemia Research</i> , <b>1987</b> , 11, 843-7	2.7	12
92	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , <b>2017</b> , 8, 91703-91710	3.3	12
91	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , <b>2021</b> , 137, 3507-3517	2.2	12
90	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 20	7	11
89	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 277-82	7.1	11
88	Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. <i>Oncotarget</i> , <b>2015</b> , 6, 1382-95	3.3	11
87	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , <b>2021</b> , 35, 3444-3454	10.7	11
86	Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. <i>Leukemia</i> , <b>2019</b> , 33, 1148-1160	10.7	11
85	The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	11
84	T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. <i>Leukemia Research</i> , <b>2007</b> , 31, 371-7	2.7	10
83	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. <i>British Journal of Haematology</i> , <b>2005</b> , 130, 878-89	4.5	10
82	Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family. <i>Redox Biology</i> , <b>2020</b> , 37, 101705	11.3	10
81	Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. <i>Annals of Hematology</i> , <b>2017</b> , 96, 159-161	3	9
80	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. <i>Haematologica</i> , <b>2017</b> , 102, e140-e143	6.6	9

79	Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. <i>Journal of Leukocyte Biology</i> , <b>2016</b> , 100, 1061-1070	6.5	9
78	KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , <b>2011</b> , 15, 198-204	1.8	9
77	Phenotypic and functional characterization of cytotoxic cells derived from endomyocardial biopsies in human cardiac allografts. <i>Cellular Immunology</i> , <b>1992</b> , 141, 332-41	4.4	9
76	Clonally expanded CD3+, CD4-, CD8- cells bearing the alpha/beta or the gamma/delta T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes. <i>Clinical Immunology and Immunopathology</i> , <b>1991</b> , 60, 371-83		9
75	Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia. <i>OncoTargets and Therapy</i> , <b>2020</b> , 13, 9679-9688	4.4	9
74	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7501-7501	2.2	9
73	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , <b>2018</b> , 9, 23443-23450	3.3	8
72	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 901-908	4.5	8
71	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8468-8479	4.8	8
70	The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. <i>Haematologica</i> , <b>2021</b> ,	6.6	8
69	Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. <i>Hematological Oncology</i> , <b>2020</b> , 38, 501-508	1.3	7
68	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , <b>2019</b> , 11,	6.6	7
67	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , <b>2017</b> , 102, 1931-1935	6.6	7
66	Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes. <i>British Journal of Haematology</i> , <b>2003</b> , 120, 765-73	4.5	7
65	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. <i>Current Cancer Drug Targets</i> , <b>2018</b> , 18, 608-616	2.8	7
64	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. <i>Hematological Oncology</i> , <b>2020</b> , 38, 823-826	1.3	7
63	Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 439-449	3.8	7
62	Frontline treatment with the combination obinutuzumab + chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 604-611	7.1	6



61	Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , <b>1999</b> , 106, 119-27	4.5	6
60	Expression of a functional p75 interleukin-2 receptor on lung lymphocytes from patients with human immunodeficiency virus type 1 (HIV-1) infection. <i>Journal of Clinical Immunology</i> , <b>1992</b> , 12, 371-80	5.7	6
59	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. <i>Journal of Clinical Immunology</i> , <b>1989</b> , 9, 401-8	5.7	6
58	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , <b>2018</b> , 36, 366-369	1.3	5
57	Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes. <i>Leukemia Research</i> , <b>1989</b> , 13, 315-22	2.7	5
56	New responsibilities for aged kinases in B-lymphomas. <i>Hematological Oncology</i> , <b>2020</b> , 38, 3-11	1.3	5
55	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 92	7	5
54	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
53	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E168-E171	7.1	5
52	Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of gene refines prognosis in treatment-naïve chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2017</b> , 102, e144-e147	6.6	4
51	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , <b>2018</b> , 132, 3118-3118	2.2	4
50	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , <b>2021</b> ,	7.8	4
49	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 637186	5.3	4
48	Leukemia reconstitution is driven by cells in early cell cycle and low metabolic state. <i>Haematologica</i> , <b>2018</b> , 103, 1008-1017	6.6	3
47	Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , <b>2018</b> , 36, 801-803	1.3	3
46	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , <b>2019</b> , 37, 508-512	1.3	3
45	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E306-E310	7.1	3
44	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. <i>Human Pathology</i> , <b>2019</b> , 85, 251-259	3.7	3

43	Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	3
42	Nerve ultrasound abnormalities mirror the course of varicella zoster virus sensory-motor radiculoplexopathy. <i>Muscle and Nerve</i> , <b>2017</b> , 55, E16-E18	3.4	2
41	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 592-8	2	2
40	Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. <i>Oncology Reports</i> , <b>2007</b> ,	3.5	2
39	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , <b>2020</b> , 136, 45-49	2.2	2
38	LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 3211-3211	2.2	2
37	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , <b>2020</b> , 4, e395	0.3	2
36	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. <i>PLoS ONE</i> , <b>2021</b> , 16, e0247717	3.7	2
35	Targeting Protein Kinases in Blood Cancer: Focusing on CK1 $\beta$ and CK2. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
34	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , <b>2021</b> , 39, 570-574	1.3	2
33	COMPLEX KARYOTYPE IN UNFIT PATIENTS WITH CLL TREATED WITH IBRUTINIB AND RITUXIMAB. THE GIMEMA LLC1114 PHASE 2 STUDY. <i>Blood</i> , <b>2021</b> ,	2.2	2
32	Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	2
31	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , <b>2020</b> , 136, 32-33	2.2	1
30	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , <b>2020</b> , 136, 33-34	2.2	1
29	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. <i>Blood</i> , <b>2018</b> , 132, 4954-4954	2.2	1
28	Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 5563-5563	2.2	1
27	A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2715-2717	3	1
26	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , <b>2021</b> , 39, 141-144	1.3	1

25	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 493-499	3.8	1
24	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. <i>Cancers</i> , <b>2021</b> , 14,	6.6	1
23	Protein Kinase CK1 $\beta$ Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 733848	5.3	0
22	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , <b>2021</b> , 39, 707-711	1.3	0
21	Anaemia during venetoclax ramp-up phase: Do not forget unusual causes.. <i>International Journal of Laboratory Hematology</i> , <b>2022</b> ,	2.5	0
20	Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. <i>Annals of Hematology</i> , <b>2018</b> , 97, 2001-2003	3	
19	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study <i>Veritas Blood</i> , <b>2020</b> , 136, 47-49	2.2	
18	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , <b>2020</b> , 136, 23-25	2.2	
17	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	
16	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 801124	5.3	
15	A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection. <i>Applied Sciences (Switzerland)</i> , <b>2022</b> , 12, 564	2.6	
14	Necrotizing Follicular Lymphoma of the Inguinal Region with Sternbergoid Cells: Clinical/Pathological Features of a Challenging Entity. <i>Applied Sciences (Switzerland)</i> , <b>2022</b> , 12, 1290	2.6	
13	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , <b>2021</b> , 138, 2641-2641	2.2	
12	Three Different Jak2/Stat3-Related Pathways Favor the Survival of Chronic Lymphocytic Leukemia Neoplastic Clone. <i>Blood</i> , <b>2018</b> , 132, 4405-4405	2.2	
11	The Combination of Complex Karyotypes/Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1844-1844	2.2	
10	Targeting Ras-Signalling Pathway to Strike Hsf1 and Induce Apoptosis in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 5533-5533	2.2	
9	HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. <i>Blood</i> , <b>2016</b> , 128, 4368-4368	2.2	
8	Gene Expression Profile Analysis of Pediatric MDS Patients Correlates with FAB Classification and Has Prognostic Relevance. <i>Blood</i> , <b>2008</b> , 112, 2695-2695	2.2	

- 7 Effects of CK2 Inhibition on Multiple Signaling Pathways in Myeloma Cells. *Blood*, **2008**, 112, 5163-5163 2.2
- 6 Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2.. *Blood*, **2009**, 114, 3840-3840 2.2
- 5 R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience. *Blood*, **2013**, 122, 3042-3042 2.2
- 4 Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 1 5.1
- 3 Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report. *Applied Sciences (Switzerland)*, **2021**, 11, 6548 2.6
- 2 Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.. *Current Oncology*, **2022**, 29, 1455-1460 2.8
- 1 Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation.. *Frontiers in Oncology*, **2022**, 12, 835290 5.3